Acne Vulgaris - Opportunity Analysis and Forecasts to 2018, New Report Launched

Pharmaceutical Giants Revisiting The Acne Arena, Deploying Notable R&D Strategies To Attain Market Share Despite its considerable patient population (estimated at 103.9 million in 2012 across the US and 5EU), the acne market has often been overlooked and has remained stagnant for the past few decades, with no novel drugs entering the arena. The market has shifted towards reformulations of existing products and/or fixed-dose combination therapies. Examples of the latter include combination products by key dermatology players, such as GALDERMAS Epiduo (adapalene and benzoyl peroxide), Glaxosmithklines (GSK) Duac (benzoyl peroxide and clindamycin phosphate), and ASTELLAS Zineryt (zinc acetate and erythromycin).

By simplifying treatment, studies have demonstrated that compliance, and therefore efficacy, can be improved by the synergistic effect of combining two active ingredients. Meanwhile, novel formulations include microsponges, liposomes, nanoemulsions, aerosol foams, subantimicrobial-dose doxycycline and extended-release minocycline. Reformulations are a low-risk strategy for Big Pharma, compared with investments into new molecular entities for acne.

Label expansions in acne have also been explored as a lifecycle management strategy, as exhibited by Galderma's entry into the large and untapped pediatric market. In February 2013, Galderma obtained a label expansion for children under 12 years of age for its lead product, Epiduo. The need for an acne treatment for children younger than 12 years of age had previously been overlooked due to safety concerns, the sensitive nature of skin in young individuals, and the rarity of the condition in children. However, recent evidence suggests that acne is more prevalent in younger individuals than it once was, potentially due to the decreasing age of onset for puberty. Targeting the previously untapped pediatric market is a strategy that Publisher expects will be followed by other dermatology companies during the coming decade.

Publisher estimates the 2012 pharmacological therapy sales for acne to total approximately $2.3 billion across the six major pharmaceutical markets covered within this report. By the end of the forecast period in 2018, acne sales are forecast to reach over $2.8 billion, growing at a CAGR of 3.9%.

Reasons to Buy

• Overview of acne, including Epidemiology, Etiology, Pathophysiology, Symptoms And Current Treatment Options
• Annualized acne prescription therapeutics market revenue, annual cost of therapy and treatment usage pattern data from 2012 to 2018
• Key topics covered include Strategic Product Assessment, Market Characterization, Unmet Needs, R&D Strategies, Clinical Trial Design, and Benchmarking Analysis for the acne prescription therapeutics market
• Pipeline Analysis: comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of late stage pipeline drugs. Accompanied by an interactive clinical and commercial benchmarking analysis tool
• Analysis of the Current and Future Market Competition in the US and 5EU acne prescription therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications
• Markets Covered - UUS, France, Germany, Italy, Spain, and The UK.

Know more about this report at : http://mrr.cm/ZPU